Pasithea Therapeutics Corp. (KTTA)

Pasithea Therapeutics Stock Forecast

Stock Price Forecast

There is currently no analyst price target forecast available for KTTA.

Analyst Consensus: n/a

Target	Low	Average	Median	High
Price	n/a	n/a	n/a	n/a
Change	n/a	n/a	n/a	n/a

Analyst Ratings

There are currently no analyst ratings available for KTTA.

Recommendation Trends

Rating	Mar '23	Apr '23	May '23	Jun '23	Jul '23
Strong Buy	1	1	1	2	0
Buy	0	0	0	0	0
Hold	0	0	0	0	0
Sell	0	0	0	0	0
Strong Sell	0	0	0	0	0
Total	1	1	1	2	0

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Elemer Piros EF Hutton	EF Hutton	Strong Buy Reiterates $40	Strong Buy	Reiterates	$40	+1,153.92%	Jul 10, 2023
Elemer Piros EF Hutton	EF Hutton	Strong Buy Initiates $40	Strong Buy	Initiates	$40	+1,153.92%	Jun 1, 2023
Constantine Davides EF Hutton	EF Hutton	Strong Buy Maintains $46 → $40	Strong Buy	Maintains	$46 → $40	+1,153.92%	Apr 3, 2023
Constantine Davides EF Hutton	EF Hutton	Strong Buy Initiates $65	Strong Buy	Initiates	$65	+1,937.62%	Dec 14, 2021

More Analyst Ratings

Financial Forecast

• Revenue This Year:
  n/a
• Revenue Next Year:
  n/a
• EPS This Year:
  n/a
• EPS Next Year:
  n/a

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023
Revenue	-	15.06K	-	-
Revenue Growth	-	-	-	-
EPS	-	-4.18	-11.04	-13.01
EPS Growth	-	-	-	-
Forward PE	-	-	-	-
No. Analysts	-	-	-	-

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue
High
Avg
Low

Revenue Growth

Revenue Growth
High
Avg
Low

EPS Forecast

EPS
High
Avg
Low

EPS Growth

EPS Growth
High
Avg
Low

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.